- Home
- NGD vs BLCO Comparison
NGD vs BLCO Comparison
Compare NGD & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- BLCO
- Stock Information
- Founded
- NGD N/A
- BLCO 1853
- Country
- NGD Canada
- BLCO Canada
- Employees
- NGD N/A
- BLCO N/A
- Industry
- NGD
- BLCO Ophthalmic Goods
- Sector
- NGD
- BLCO Health Care
- Exchange
- NGD Nasdaq
- BLCO Nasdaq
- Market Cap
- NGD 3.8B
- BLCO 4.3B
- IPO Year
- NGD 2004
- BLCO 2022
- Fundamental
- Price
- NGD $4.91
- BLCO $13.77
- Analyst Decision
- NGD Buy
- BLCO Hold
- Analyst Count
- NGD 2
- BLCO 13
- Target Price
- NGD $4.75
- BLCO $15.63
- AVG Volume (30 Days)
- NGD 25.9M
- BLCO 746.6K
- Earning Date
- NGD 07-29-2025
- BLCO 07-30-2025
- Dividend Yield
- NGD N/A
- BLCO N/A
- EPS Growth
- NGD N/A
- BLCO N/A
- EPS
- NGD 0.17
- BLCO N/A
- Revenue
- NGD $941,500,000.00
- BLCO $4,829,000,000.00
- Revenue This Year
- NGD $38.67
- BLCO $6.97
- Revenue Next Year
- NGD $42.20
- BLCO $5.48
- P/E Ratio
- NGD $29.49
- BLCO N/A
- Revenue Growth
- NGD 21.17
- BLCO 11.94
- 52 Week Low
- NGD $1.92
- BLCO $10.45
- 52 Week High
- NGD $5.16
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- NGD 59.95
- BLCO 72.31
- Support Level
- NGD $4.70
- BLCO $12.02
- Resistance Level
- NGD $5.16
- BLCO $12.31
- Average True Range (ATR)
- NGD 0.17
- BLCO 0.46
- MACD
- NGD -0.03
- BLCO 0.20
- Stochastic Oscillator
- NGD 52.78
- BLCO 99.57
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.